faculty photo

Richard L. Dunbar

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Academic Office:
Perelman School of Medicine at the University of Pennsylvania
3600 Spruce Street, 9-010 Maloney Building

Clinic:
Preventive Cardiovascular Medicine Clinic
3400 Civic Center Blvd, 2nd Floor, East Pavilion
Philadelphia, PA 19104
Office: Clinic (215) 615-8659
Lab: (215) 315-3378
Education:
B.A. (Environmental Sciences)
University of Virginia, Charlottesville, VA, 1992.
M.D. (Medicine)
Medical College of Virginia, Richmond, VA, 1997.
M.S. (Translational Research)
University of Pennsylvania School of Medicine, Philadelphia, PA, 2008.
Permanent link
 

Description of Research Expertise

Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research.

Description of Clinical Expertise

Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine

Selected Publications

Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Moriarty PM: Retrospective Review of the Effect of Alirocumab on Apheresis. J Clin Lip 11(3), May 2017 Notes: [Accepted for poster presentation to the 2017 National Lipid Association Scientific Sessions]

Ueda M, Burke FM, Walters L, Lalic D, Sikora, Greene H, DerOhannessian S, McIntyre A, deGoma E, Hegele RA, Rader DJ, Dunbar RL: Familial Chylomicron Syndrome: Importance of Discerning the Rare Among the Common. J Clin Lip 11(3), May 2017 Notes: [Accepted for poster presentation to the 2017 National Lipid Association Scientific Sessions]

Cuchel M, Raper AC, Pryma DA, Freifelder RH, Poria R, Cromley D, Li X, Dunbar RL, French B, Qu L, Farver W, Su C-C, Lund-Katz S, Baer A, Ruotolo G, Akerblad P, Ryan CS, Xiao L, Kirchgessner TG, Millar JS, Billheimer JT, Rader DJ : A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans. J Lipid Res April 2017 Notes: Published Online 2/2017, Print 4/2017.

Dewey FE*, Gusarova V*, Dunbar RL*, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV , Bruse S, Dansky HM , Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH , Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-D I on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ on behalf of the Geisinger-Regeneron DiscovEHR Collaboration, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A : Genetic and Pharmacologic Inactivation of ANGPTL3 and Atherosclerotic Cardiovascular Disease. NEJM April 2017 Notes: [*Co-First Authors, Accepted April 2017]

Dunbar RL*, Goel H*, Tuteja S, Song W-L, Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL: Measuring Physical Stigmata of Niacin-Associated Skin Toxicity by Colorimetry, White-Light Spectroscopy, Laser Doppler Flowmetry, and Thermometry in Combination with Symptom Perception Scoring: Methods to Aid Development of Niacin Mimetics. J Lipid Res April 2017 Notes: Co-First Authors, Published Online 1/2017 in Print 4/2017.

Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G: Effects of CETP Inhibition with Anacetrapib on Metabolism of VLDL TG and Plasma Apolipoproteins C-II, C-III, and E. J Lipid Res March 2017.

Ueda M*, Dunbar RL*, Wolska A, Sikora TU, del Rosario Escobar M, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, Remaley AT, Rader DJ: A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency with Severe Triglyceridemia and Pancreatitis. J Clin Endocrinol Metab 102, February 2017 Notes: Co-First Author.

Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, MD, Lader E, Rader DJ : Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2 (HCA2), and response to niacin therapy Pharmacogenetics and Genomics 2017 Notes: [Provisionally Accepted]

Dunbar RL, Bouzelmat A, Gipe DA, Pordy R, Sasiela W, Mellis S, Banerjee P : Inhibition Of ANGPTL3 By Evinacumab Reduced Triglycerides (TGs) And LDL-C In Subjects Presenting With Modest Elevations In TGs And/or LDL-C, Recapitulating The Hypolipidemic Effects Of Loss-of-function (LoF) Mutations Of ANGPTL3. Circulation Novemeber 2016 Notes: [Oral Presentation to the American Heart Association Scientific Sessions 2016, New Orleans, LA]

Digenio A*, Dunbar RL*, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care 39(8): 1408-1415, August 2016 Notes: Co-first author.

back to top
Last updated: 05/17/2017
The Trustees of the University of Pennsylvania